The Serum Institute of India will try to launch an Omicron-specific vaccine for COVID-19 after six months, its CEO Adar Poonawalla said on Thursday.
Speaking to reporters on the sidelines of an event, he said there is good data available for Covavax vaccine.
"The original Novovax vaccine Covovax covers omicron and there is good data for it. We will try to launch Omicron-specific vaccine after six months," he said.
The Pune-based Serum Institute is working with US biotechnology major Novavax to bring the Omicron-specific vaccine.
Omicron sub-variant of the COVID-19 was declared as a variant of concern by the World Health Organisation due to its fast transmission and infection rate.
The company's Covavax vaccine is available for those above the age of 12 in the country.
On monkeypox, Mr Poonawalla said the need for a vaccine for is "debatable".
"Yes, it created a little bit of buzz when we saw the cases here. We are conducting research on the topic and can collaborate with the Department of Biotechnology on it too. Our research is going on and we will see in six months," he said.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Jaaved Jaaferi Teases Karan Johar After Adar Poonawalla Buys 50% Stake In Dharma Productions Karan Johar's Dharma Productions Sells 50% Stake To Adar Poonawalla For Rs 1000 Crore Serum Institute's New "High Efficacy" Malaria Vaccine Rolls Out In Africa Video: Man Sits On Firecracker In Bet For New Vehicle. Explosion Kills Him Charges Drawn Up In Kolkata Rape-Murder Case, Accused Says "Framed" "Cowardly Attempts To Intimidate Diplomats": PM's 1st Comments On Canada Row 3 Women Injured In Car Accident In North Delhi's Civil Lines VITEEE 2025: Registration Begins, Exams Start On April 21, Check Details Assam Police Rescue 19 Dogs, Arrest 4 In Crackdown On Illegal Smuggling Track Latest News Live on NDTV.com and get news updates from India and around the world.